Abstract

Behcet’s syndrome is an inflammatory, chronic, recurrent, multisystemic disease, common in men 25-40 years of age, with immunological determinism (including autoimmune) in the presence of infectious (bacterial) triggering agents and genetic involvement through the presence of HLA-B51. Behcet’s syndrome is characterized by a symptomatic triad of: recurrent nongranulomatous uveitis with hypopyon, oral and genital ulcers, and skin changes. Iridocyclitis (anterior uveitis) with acute, recurrent hypopyon is the most common ocular manifestation in Behcet’s syndrome and progresses to unpredictable outbreaks with sequelae and severe complications that cause loss / loss of vision. Ocular manifestations in Behcet’s syndrome are also accompanied by posterior pole involvement with posterior uveitis, venous and arterial occlusive vasculitis, necrotizing retinitis, macular edema, cystoid macular edema, which accentuates the decrease / loss of vision.Treatment of Behcet’s syndrome should be adapted to the chronic course of the disease and should be aggressive from the outset through systemic drug combinations: corticosteroid / immunosuppressive / immunomodulatory therapy and appropriate ophthalmic treatment: cycloplegics, antiglaucoma eye drops, filter surgery, cataract surgery, cataract surgery under cortisone protection, endoocular surgery, laser photocoagulation. Ophthalmologist / internist interdisciplinary collaboration is required.

Statistics